← Back to Clinical Trials
Recruiting NCT07059858

NCT07059858 Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07059858
Status Recruiting
Phase
Sponsor Abant Izzet Baysal University
Condition Intellectual Disability
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-09-28
Primary Completion 2026-03-02

Trial Parameters

Condition Intellectual Disability
Sponsor Abant Izzet Baysal University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 5 Years
Max Age 12 Years
Start Date 2025-09-28
Completion 2026-03-02

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Many neurodevelopmental, psychiatric, and medical disorders are commonly associated with intellectual disability. The presence of neurodevelopmental and psychiatric (NDP) comorbidities has been reported to negatively impact the clinical outcomes of bowel or bladder dysfunction. Pediatric bladder and bowel dysfunction (BBD) is a common but underdiagnosed condition characterized by a spectrum of lower urinary tract symptoms and is often associated with constipation. Lower urinary tract symptoms include dysuria, urinary urgency, daytime incontinence, and enuresis, while bowel symptoms include constipation and encopresis. Most BBD cases are functional and not neurogenic in origin. In children with special needs, all types of urinary incontinence are reported to occur more frequently compared to children without developmental or behavioral disabilities. Intellectual disability (IQ \<70) is also identified as a significant risk factor for urinary incontinence, with prevalence increasing as IQ decreases. In these children, lower urinary tract symptoms such as overactive bladder, dysfunctional voiding, and low fluid intake are also observed. Furthermore, according to support plans and medical records, 94% of individuals with intellectual and multiple disabilities experience constipation. Interestingly, lower levels of intellectual disability (profound and severe ID) have been associated with a lower prevalence of constipation. Although there are studies in the literature examining bladder and bowel functions separately in specific diagnostic groups with intellectual disability, the number of studies that assess bladder and bowel functions together in children with any form of intellectual disability is limited. Moreover, to our knowledge, there is no study in the literature that evaluates bladder and bowel functions along with child participation and parental quality of life in children with intellectual disability. Based on this gap in the literature, the aim of our study is to examine bladder and bowel functions, participation, and quality of life in children with intellectual disability

Eligibility Criteria

Inclusion Criteria: For Children with Intellectual Disabilities: * Aged between 5 and 12 years * Diagnosed with mild, moderate, or severe intellectual disability as documented by the ÇÖZGER (Child Special Needs Report) * Both the parent and the child agree to participate in the study For Typically Developing Children * Aged between 5 and 12 years * Both the parent and the child agree to participate in the study Exclusion Criteria: For Children with Intellectual Disabilities: * Having a diagnosis of physical disability * Presence of a neurological anomaly affecting bladder and bowel functions * Parent does not consent to participate in the study * Having undergone trauma or surgery affecting bladder and bowel functions within the last 6 months * Diagnosis of a genetic disorder * Use of medications that may affect bladder and bowel functions For Typically Developing Children * Presence of a neurological anomaly affecting bladder and bowel functions * Lack of parental consent to participa

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology